KALV
HEALTHCAREKalVista Pharmaceuticals Inc
$26.72+0.01 (+0.04%)PRE
Live · NASDAQ · May 8, Close
AI Insight
What's Moving KALV Today?
No stock-specific AI insight has been generated for KALV yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$9.83$26.84
$26.72
Fundamentals
Market Cap$1.4B
P/E Ratio—
EPS$-3.94
Dividend Yield—
Dividend / Share—
ROE-1.9%
Profit Margin-2.2%
Debt / Equity—
Trading
Volume6.5M
Avg Volume (10D)—
Shares Outstanding53.2M
KALV News
20 articles- Chiesi widens rare disease portfolio with $1.9bn KalVista buyoutPharmaceutical-technology·Apr 30, 2026
- IBT portfolio manager says KalVista deal signals Biotech 2.0 growthYahoo Finance·Apr 30, 2026
- Stock Market Today, April 29: KalVista Pharmaceuticals Surges on Chiesi Group Acquisition AnnouncementMotley Fool·Apr 29, 2026
- KalVista Scores $1.9 Billion Takeover Deal; Why A Key Rival Jumped TooYahoo Finance·Apr 29, 2026
- Sector Update: Health Care Stocks Fall Late AfternoonYahoo Finance·Apr 29, 2026
- Top Midday Stories: Visa Shares Rise After Strong Q2 Earnings, $20 Billion Buyback Program; Robinhood Misses Q1 EPS, Revenue TargetsYahoo Finance·Apr 29, 2026
- Top Premarket GainersYahoo Finance·Apr 29, 2026
- Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease PortfolioYahoo Finance·Apr 29, 2026
- Chiesi to buy KalVista in $1.9B deal for rare disease drugBiopharmadive·Apr 29, 2026
- KalVista Pharmaceuticals Touts EKTERLY Launch: Nearly $50M in Under 6 Months, 20% Patient ReachMarketbeat·Apr 16, 2026
- KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare ConferenceYahoo Finance·Apr 8, 2026
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Apr 2, 2026
- KalVista Pharmaceuticals (KALV) Is Up 22.4% After Early Success In Pivotal Pediatric HAE TrialYahoo Finance·Apr 1, 2026
- KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership ConferenceYahoo Finance·Mar 30, 2026
- KalVista Pharmaceuticals, Inc. Q1 2025 Earnings Call SummaryMoby·Mar 26, 2026
- KalVista Pharmaceuticals Inc (KALV) Q4 2025 Earnings Call Highlights: Strong Launch of EKTERLY ...Yahoo Finance·Mar 25, 2026
- KalVista Pharmaceuticals Q4 Earnings Call HighlightsMarketbeat·Mar 25, 2026
- KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Mar 25, 2026
- KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 2026 Global Angioedema Leadership ConferenceYahoo Finance·Mar 20, 2026
- KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026Yahoo Finance·Mar 18, 2026
All 20 articles loaded
Price Data
Open$0.00
Previous Close$26.71
Day High$0.00
Day Low$0.00
52 Week High$26.84
52 Week Low$9.83
52-Week Range
$9.83$26.84
$26.72
Fundamentals
Market Cap$1.4B
P/E Ratio—
EPS$-3.94
Dividend Yield—
Dividend / Share—
ROE-1.9%
Profit Margin-2.2%
Debt / Equity—
Trading
Volume6.5M
Avg Volume (10D)—
Shares Outstanding53.2M
About KalVista Pharmaceuticals Inc
KalVista Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, discovers, develops, and markets small-molecule protease inhibitors for illnesses with unmet needs. The company is headquartered in Cambridge, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—